NCT02927925 2021-01-14A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal TypeJanssen Research & Development, LLCPhase 2 Completed32 enrolled 17 charts